Williams AR, et al. - Given buprenorphine treatment is discontinued within a few weeks or months in most of the patients with opioid use disorder despite experiencing a reduction in the risk of overdose and death, researchers compared adverse health consequences after buprenorphine discontinuation in patients who were successfully retained beyond 6 months of continuous therapy, a minimum treatment duration recently endorsed by the National Quality Forum. For this purpose, they undertook a retrospective longitudinal cohort study utilizing the MarketScan multistate Medicaid claims database (2013–2017), incorporating 12 million beneficiaries yearly. Findings revealed a high risk of acute care service use and overdose after buprenorphine discontinuation regardless of treatment duration. With treatment duration beyond 15 months, superior results became important, although rates of the primary adverse consequences continued to be high.